Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial.

Richard CowanJ J ScarisbrickP L ZinzaniJ P NicolayL SokolL Pinter-BrownPietro QuaglinoL IversenReinhard DummerA MusiekF FossT ItoJ-P RosenM C Medley

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2021)

This post hoc analysis indicates greater clinical benefit with mogamulizumab vs. vorinostat in patients with MF and SS classified as having B1 and B2 blood involvement.

Keyphrases

study protocol
clinical trial
case report
phase iii
phase ii
randomized controlled trial
risk factors